Form 4: Charles River Laboratories CEO James C. Foster Reports Stock Transaction

James C. Foster, CEO of Charles River Laboratories, reports the acquisition of 6,075 shares of common stock and a transfer of 20,000 shares to a GRAT account.

Summary

• On February 20, 2025, James C. Foster, the Chairman, President, and CEO of Charles River Laboratories, filed a Form 4.
• The form reports a transaction where Foster acquired 6,075 shares of common stock at a price of $165.01 per share.
• Additionally, 20,000 shares were transferred from direct holdings to a 2025 Grantor Retained Annuity Trust (GRAT) account.
• Following the reported transactions, Foster directly owns 183,639 shares of common stock.
• Foster also has indirect ownership through various trusts and a spousal holding.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports a stock transaction, with the CEO's purchase potentially viewed as a mildly positive signal.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the CEO's stock purchase could imply confidence in the company's future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive indicator.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, James C. Foster, Charles River Laboratories, CRL, stock transaction, beneficial ownership, GRAT